Opinion|Videos|December 30, 2024
Administering Bispecifics in the Community vs Academic Centers
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss understanding the comparative advantages, decision-making factors, infrastructure requirements, and partnership models for administering bispecific antibodies in community vs academic settings, with particular focus on patient care logistics and referral pathways.
Advertisement
Episodes in this series
Video content above is prompted by the following
- What are the benefits of administering bispecific antibodies in the community setting compared with tertiary centers?
- What factors might influence the decision to administer these agents at an academic center instead of in a community setting?
- What kind of infrastructure is needed to administer these agents in the community setting that poses key challenges?
- How are you partnering with academic or community centers to support these patients? What is your internal referral pathway?
Advertisement
Related to this article
September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
Biologic Stewardship: The Next Frontier for Health System Pharmacists
5